指南与共识消化道肿瘤放疗姑息放疗与转移瘤

ESTRO局部复发直肠癌再程放疗推荐:ASTRO认可

ESTRO recommendations for the use, planning and delivery of reirradiation in locally recurrent rectal cancer - Endorsed by ASTRO.
指南 / 共识 · Radiother Oncol · 2026-06-27

ESTRO下消化道肿瘤小组依据PRISMA系统综述制定局部复发直肠癌再程放疗推荐,覆盖适应证、计划与实施共14个关键问题,推荐多基于低级别证据或专家共识,强调患者选择、既往治疗考量与精准技术以确保安全实施。

要点

  • 再程放疗可用于新辅助、根治性治疗和姑息治疗场景。
  • 推荐基于低级别证据或专家共识,亟需前瞻性研究与登记数据。
  • 需综合既往直肠癌治疗、器官剂量指导和患者目标制定计划。

核心结论

  • 局部复发直肠癌的(化疗)再程放疗可用于新辅助、根治性和姑息治疗,以提高根治性切除率、增强局部控制并改善症状控制。
  • 最佳患者选择联合先进影像和精准技术,是最大化治疗获益并减少损害的关键。

研究设计与样本

  • 由ESTRO指南委员会下消化道肿瘤小组组建写作委员会,按PRISMA指南进行系统文献综述,回答14个关于局部复发直肠癌再程放疗适应证、计划和实施的关键问题。
  • 推荐基于现有证据或专家共识,采用ASTRO分级系统进行分级。

主要发现

  • 几乎所有证据级别均为低级别,推荐大多基于低质量证据或专家意见,凸显前瞻性研究和登记数据的迫切需求。
  • 谨慎的患者选择、考虑治疗意图、结合既往直肠癌治疗的治疗计划、器官剂量指导和患者目标是优化结局并减少不良反应的关键。

关键数值与推荐

  • 原文提及再程放疗剂量(EQD2Gy)≥30 Gy与显著不良反应担忧相关,但未报告具体推荐剂量阈值。

临床怎么用

  • 在缺乏高级别证据的情况下,这些推荐代表专家共识,为常规临床实践中安全、一致地实施(化疗)再程放疗提供实用指导。

局限性

  • 证据级别低,推荐主要基于低质量证据或专家意见,缺乏前瞻性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Reirradiation for locally recurrent rectal cancer (LRRC) has historically been restricted by concerns regarding significant adverse effects, particularly with reirradiation doses (in EQD2Gy) ≥ 30 Gy. Advances in radiation technology now enable safer delivery, renewing interest in (chemo)reirradiation as part of multimodal management. Given the scarcity of prospective data and the considerable variability in radiotherapy approaches, there is a clear need for recommendations to enhance treatment homogeneity and quality. METHODS: A writing committee was established by the Lower Gastrointestinal Cancer Sub-Committee of the European Society for Radiotherapy and Oncology (ESTRO) Guidelines Committee. We performed a systematic literature review following PRISMA guidelines; aiming to answer 14 key questions regarding the indications, planning and delivery of reirradiation in LRRC. Recommendations were based on available evidence or expert consensus and graded using the American Society for Radiation Oncology (ASTRO) grading system. RESULTS: Careful patient selection, consideration of treatment intent, treatment planning taking into account prior rectal cancer treatment, organ dose guidance and patient goals are essential to optimize outcomes and minimize adverse effects. The key questions guided a summary of appropriate literature and a series of recommendations to support the implementation of reirradiation in LRRC into routine clinical care. Almost all levels of evidence were low with recommendations mostly based on low quality of evidence or expert opinion, underscoring the urgent need for prospective studies and registry data. CONCLUSIONS: (Chemo)reirradiation in LRRC can be applied in the context of neoadjuvant treatment, definitive treatment and palliation, to increase radical resection rate, enhance local control and improve symptom control. Optimal patient selection, along with advanced imaging and precision techniques, is essential to maximize the therapeutic benefit while minimizing harm. In the absence of high-level evidence, these recommendations represent expert consensus and provide practical guidance to ensure the safe and consistent delivery of (chemo)reirradiation in routine clinical practice.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Peulen HMU, Rønde HS, Kronborg C, et al. ESTRO recommendations for the use, planning and delivery of reirradiation in locally recurrent rectal cancer - Endorsed by ASTRO. Radiother Oncol. 2026. PMID: 42364818. doi:10.1016/j.radonc.2026.111647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。